Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03207256
Title Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors TG Therapeutics, Inc.
Age Groups: child | senior | adult
Covered Countries USA

No variant requirements are available.